
GRDN Stock Forecast & Price Target
GRDN Analyst Ratings
Bulls say
Guardian Pharmacy Service is positioned to benefit from the growing demand for long-term care pharmacy services, driven by an aging population and a fragmented industry ripe for consolidation. The company's strong financial position and proven operating model make it well-suited to capitalize on this opportunity. Additionally, favorable factors such as improved vaccine economics and increased Medicare Part D mix further support a positive outlook for the company's future growth and profitability. As a result, analysts have raised their estimates and price targets for Guardian Pharmacy Service, with one predicting a price target of $38. Based on these factors, the current outlook remains bullish and the stock is currently rated as a Buy.
Bears say
Guardian Pharmacy Service is experiencing positive growth with their recent acquisition and pipeline expansion. However, there are risks associated with their rating and price target, including potential regulatory changes and challenges with relationship management, staffing, supply chain, acquisitions, and reliance on technology. Their strong financial flexibility and technology capabilities stand out as differentiators in the market, but margin impacts from recent expansion may continue in the short term.
This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.
GRDN Analyst Forecast & Price Prediction
Start investing in GRDN
Order type
Buy in
Order amount
Est. shares
0 shares